Bioq Pharma Inc., of San Francisco, said the Australian Therapeutic Goods Administration has approved the company's Ropivacaine Readyfusor for the treatment of postsurgical pain in adults via continuous peripheral nerve block and continuous wound infiltration. It's a disposable, ready-to-use, single-use infusion product prefilled by the manufacturer with 0.2 percent ropivacaine, a non-narcotic local anesthetic.